Explore Our Publications
Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Upcoming Presentations
-
Preclinical Efficacy of ENTR-601-50, a Novel EEV™-Oligonucleotide Construct for the Treatment of Exon 50 Skip–Amenable Duchenne Muscular Dystrophy
- By: Haoming Liu, PhD, Principal Scientist, Entrada Therapeutics
- At: 21st Annual Meeting of the Oligonucleotide Therapeutics Society
- On: October 19, 2025
October 19, 2025
Past Presentations
-
ELEVATE-44-201, a Phase 1/2b Study to Assess the Safety and Efficacy of ENTR-601-44 in Patients With DMD Amenable to Exon 44 Skipping
- By: Laurent Servais, MD, PhD, MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research, University of Oxford, and Neuromuscular Reference Centre, University Hospital of Liège
- At: 30th Annual Congress of the World Muscle Society
- On: October 7, 2025
DownloadOctober 7, 2025 -
ELEVATE-45-201, a Phase 1/2b Study to Assess the Safety and Efficacy of ENTR-601-45 in Patients With DMD Amenable to Exon 45 Skipping
- By: Giovanni Barnello, MD, PhD, UCL Great Ormond Street Institute of Child Health
- At: 30th Annual Congress of the World Muscle Society
- On: October 7, 2025
DownloadOctober 7, 2025 -
Preclinical Efficacy of ENTR-601-50, a Novel EEV™-Oligonucleotide Construct for the Treatment of Exon 50 Skip–Amenable Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President, Therapeutic Research and External Innovation Lead, Entrada Therapeutics
- At: 30th Annual Congress of the World Muscle Society
- On: October 7, 2025
DownloadOctober 7, 2025 -
EEV-mediated Delivery to Satellite Cells: Towards a Comprehensive Correction of Pathophysiology in a Preclinical Model of Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President, Therapeutic Research and External Innovation Lead, Entrada Therapeutics
- At: International Conference on Muscle Wasting
- On: September 25, 2025
DownloadSeptember 25, 2025 -
Endosomal Escape Vehicle Platform Safely and Effectively Delivers Oligonucleotide Therapeutics to Skeletal and Cardiac Muscle Tissue for the Potential Treatment of Duchenne Muscular Dystrophy
- By: Patrick Dougherty, PhD, Principal Scientist, Discovery Research, Entrada Therapeutics
- At: ACS Fall 2025
- On: August 18, 2025
DownloadAugust 18, 2025 -
Development of the Endosomal Escape Vehicle (EEV™) Platform for Enhanced Delivery of Oligonucleotides to Skeletal and Cardiac Muscle
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: 6th International Caparica Conference on Splicing
- On: July 21, 2025
DownloadJuly 21, 2025